Treatment(s) now being considered-Bone marrow transplant Posts on Medivizor
Navigation Menu

Treatment(s) now being considered-Bone marrow transplant Posts on Medivizor

Can a stem cell transplant improve outcomes of patients with cHL after nivolumab treatment?

Posted by on Feb 29, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of a stem cell transplant after nivolumab (Opdivo) therapy in patients with classical Hodgkin’s lymphoma (cHL) that came back or stopped responding to treatment. This study concluded that nivolumab followed by stem cell transplant is safe and effective for these patients. Some background...

Read More

What factors can predict the success of stem cell transplantation for patients with lymphoma?

Posted by on Nov 3, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the risk factors associated with delayed engraftment in patients who had stem cell transplantation (SCT). The authors found that patients receiving blood transfusions, those with low platelet levels, and those given low numbers of stem cells during SCT were more likely to experience DE. Some...

Read More

Evaluating outcomes after haploSCT for patients with classical Hodgkin lymphoma

Posted by on Jun 25, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of patients with classical Hodgkin lymphoma (cHL) after reduced-intensity chemotherapy and haploidentical stem cell transplantation (haploSCT). This study concluded that this treatment approach is as effective as allogeneic SCT (alloSCT), but with fewer long-term complications. Some background...

Read More

The effects of brentuximab vedotin in patients with unresponsive Hodgkin Lymphoma

Posted by on Sep 18, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the effects of brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma after stem cell transplant. Brentuximab vedotin appeared to be effective and safe for these patients. Some background Many patients with Hodgkin lymphoma (HL) are cured by standard therapies. However, some patients lose...

Read More

Is tandem stem cell transplantation effective in high risk relapsed/refractory Hodgkin lymphoma

Posted by on May 26, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the effect of tandem stem cell transplantation (SCT) in patients with high-risk relapsed/refractory Hodgkin Lymphoma (HL). The main finding was that patients treated with tandem SCT had greater progression-free survival than those without. Some background A SCT involves the transfer of stem cells into the patient to...

Read More

What are the long-term outcomes for HL patients receiving plerixafor before a stem cell transplant?

Posted by on May 7, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study compared the long-term outcomes of Hodgkin’s lymphoma (HL) patients who received plerixafor (Mozobil) to those who did not prior to autologous stem cell transplantation (autoSCT). This study concluded that plerixafor-treated patients had similar outcomes as patients who received conventional regimens. Some background...

Read More

Does high-dose GBM chemotherapy lead to better post-stem cell transplant outcomes compared to BEAM in refractory or relapsed Hodgkin’s lymphoma patients?

Posted by on May 3, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the outcomes of primary refractory or relapsed Hodgkin’s lymphoma (HL) patients who received GBM (gemcitabine, busulfan, melphalan) or BEAM (carmustine, etoposide, cytarabine, melphalan) chemotherapy before autoSCT (autologous stem cell transplantation). This study concluded that GBM improved patient outcomes...

Read More

What are the long-term outcomes after plerixafor and G-CSF before stem cell transplantation?

Posted by on Mar 8, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the long-term outcomes of patients with non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM) who received plerixafor (Mozobil) or placebo combined with G-CSF (granulocyte colony stimulating factor) before a stem cell transplant (SCT). This study concluded that adding plerixafor to G-CSF did not negatively...

Read More

Do two cycles of stem cell therapy lead to longer progression free survival in relapsed or refractory HL patients?

Posted by on Feb 27, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study determined if progression-free survival (time from treatment before disease progression) could be improved in patients with relapsed or refractory Hodgkin’s lymphoma (HL) who received two cycles (tandem) of autologous hematopoietic stem cell transplantation (AHSCT). This study concluded that tandem AHSCT appears effective...

Read More